Isabelle Quere

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3110227/publications.pdf

Version: 2024-02-01

192 papers 17,768 citations

³⁸⁷⁴² 50 h-index

129 g-index

234 all docs 234 docs citations

times ranked

234

18123 citing authors

#	Article	IF	CITATIONS
1	Acute effects of graduated and progressive compression stockings on leg vein cross-sectional area and viscoelasticity in patients with chronic venous disease. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2022, 10, 186-195.e25.	1.6	2
2	Wounds in chronic leg oedema. International Wound Journal, 2022, 19, 411-425.	2.9	8
3	Reference values of coagulation assays performed for thrombophilia screening after a first venous thrombosis and their intra-patient associations. Thrombosis Research, 2022, 210, 94-103.	1.7	2
4	UEMS training requirements for angiology/vascular medicine. European standards of postgraduate medical specialist training. 2022 up-dated version. International Angiology, 2022, , .	0.9	2
5	Correlation of nailfold capillaroscopy findings with history of digital ulcer on same finger: Results of SCLEROCAP study. Microvascular Research, 2022, 142, 104365.	2.5	2
6	Somatic <i>TEK</i> variant with intraarticular venous malformation and knee hemarthrosis treated with rapamycin. Molecular Genetics & Enomic Medicine, 2022, , e1931.	1.2	2
7	Postthrombotic syndrome and quality of life after deep vein thrombosis in patients treated with edoxaban versus warfarin. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12748.	2.3	2
8	Clinical Presentation and Short- and Long-term Outcomes in Patients With Isolated Distal Deep Vein Thrombosis vs Proximal Deep Vein Thrombosis in the RIETE Registry. JAMA Cardiology, 2022, 7, 857.	6.1	15
9	Primary lymphedema French National Diagnosis and Care Protocol (PNDS; Protocole National de) Tj ETQq1 1 0.7	84314 rgE 2.7	BT /Qverlock 1
10	Severe adverse events during sirolimus "off″abel―therapy for vascular anomalies. Pediatric Blood and Cancer, 2021, 68, e28936.	1.5	28
11	International Camps for Children with Lymphedema and Lymphatic Anomalies: When Education Links with Psychosocial Research. Lymphatic Research and Biology, 2021, 19, 36-40.	1.1	3
12	Prognostic Significance of Concomitant Superficial Vein Thrombosis in Patients with Deep Vein Thrombosis of the Lower Limbs. Thrombosis and Haemostasis, 2021, 121, 1650-1659.	3.4	3
13	Quality of life in patients with pulmonary embolism treated with edoxaban versus warfarin. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12566.	2.3	3
14	Triaging acute pulmonary embolism for home treatment by Hestia or simplified PESI criteria: the HOME-PE randomized trial. European Heart Journal, 2021, 42, 3146-3157.	2.2	64
15	Quality of Life and Costs Within Decongestive Lymphatic Therapy in Patients with Leg Lymphedema: A Multicountry, Open-Label, Prospective Study. Lymphatic Research and Biology, 2021, 19, 423-430.	1.1	6
16	Development of Self-Efficacy Tools for Parents and Professionals Caring for Children and Young People with Lymphedema (ILF Parent SE and ILF Professional SE). Lymphatic Research and Biology, 2021, 19, 460-467.	1.1	1
17	"l Cry. I Simply Cry.―An Ethnography of a Lymphedema Summer Camp. Lymphatic Research and Biology, 2021, 19, 479-487.	1.1	1
18	Primary lymphoedema. Nature Reviews Disease Primers, 2021, 7, 77.	30.5	33

#	Article	IF	Citations
19	Factors Predicting Limb Volume Reduction Using Compression Bandaging Within Decongestive Lymphatic Therapy in Lymphedema: A Multicountry Prospective Study. Lymphatic Research and Biology, 2021, 19, 412-422.	1.1	5
20	Skin Layer Thickness and Shear Wave Elastography Changes Induced by Intensive Decongestive Treatment of Lower Limb Lymphedema Lymphatic Research and Biology, 2021, , .	1.1	0
21	Longâ€ŧerm risk of postthrombotic syndrome after symptomatic distal deep vein thrombosis: The CACTUSâ€PTS study. Journal of Thrombosis and Haemostasis, 2020, 18, 857-864.	3.8	24
22	Epidemiology and 3â€year outcomes of combined oral contraceptive–associated distal deep vein thrombosis. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 1216-1223.	2.3	8
23	Noninvasive measurement of venous wall deformation induced by changes in transmural pressure shows altered viscoelasticity in patients with chronic venous disease. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2020, 9, 987-997.e2.	1.6	0
24	COVID-19 associated coagulopathy: The crowning glory of thrombo-inflammation concept. Anaesthesia, Critical Care & Description (2020, 39, 381-382).	1.4	23
25	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. Thrombosis and Haemostasis, 2020, 120, 1004-1024.	3.4	206
26	Pulmonary embolism home treatment: What GP want?. Thrombosis Research, 2020, 187, 180-185.	1.7	3
27	Uncertainties on the prognostic value of Dâ€dimers in COVIDâ€19 patients. Journal of Thrombosis and Haemostasis, 2020, 18, 2066-2067.	3.8	20
28	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. Journal of the American College of Cardiology, 2020, 75, 2950-2973.	2.8	2,392
29	Biphasic Temporal Relationship between Cancers and Systemic Sclerosis: A Clinical Series from Montpellier University Hospital and Review of the Literature. Journal of Clinical Medicine, 2020, 9, 853.	2.4	15
30	Assessment of primary lymphedema and post-thrombotic lower limb edema patient's pathway. JMV-Journal De Medecine Vasculaire, 2020, 45, 55-61.	0.2	1
31	Hokusai post-PE study: a follow-up study on long-term outcomes of pulmonary embolism in patients treated with edoxaban vs warfarin. , 2020, , .		0
32	Clinical and Ethical Challenges in Undertaking LIMPRINT in Vulnerable Populations. Lymphatic Research and Biology, 2019, 17, 155-162.	1.1	3
33	Effect of anticoagulant treatment on pain in distal deep vein thrombosis: an ancillary analysis from the cactus trial. Journal of Thrombosis and Haemostasis, 2019, 17, 507-510.	3.8	7
34	Out-of-pocket payments, vertical equity and unmet medical needs in France: A national multicenter prospective study on lymphedema. PLoS ONE, 2019, 14, e0216386.	2.5	8
35	LIMPRINT: Health-Related Quality of Life in Adult Patients with Chronic Edema. Lymphatic Research and Biology, 2019, 17, 163-167.	1.1	26
36	A Study Using Visual Art Methods to Explore the Perceptions and Barriers of Self-Management in Children and Adolescents with Lymphedema. Lymphatic Research and Biology, 2019, 17, 231-244.	1.1	8

#	Article	IF	CITATIONS
37	A Study to Explore the Professional Conceptualization and Challenges of Self-Management in Children and Adolescents with Lymphedema. Lymphatic Research and Biology, 2019, 17, 221-230.	1.1	8
38	A Study to Explore the Parental Impact and Challenges of Self-Management in Children and Adolescents Suffering with Lymphedema. Lymphatic Research and Biology, 2019, 17, 245-252.	1.1	7
39	The Development and Validation of the LIMPRINT Methodology. Lymphatic Research and Biology, 2019, 17, 127-134.	1.1	18
40	LIMPRINT in Specialist Lymphedema Services in United Kingdom, France, Italy, and Turkey. Lymphatic Research and Biology, 2019, 17, 141-146.	1.1	14
41	Vena cava filters in patients presenting with major bleeding during anticoagulation for venous thromboembolism. Internal and Emergency Medicine, 2019, 14, 1101-1112.	2.0	9
42	LIMPRINT: A Sociological Perspective on "Chronic Edema― Lymphatic Research and Biology, 2019, 17, 168-172.	1.1	7
43	LIMPRINT: The UK Experienceâ€"Subjective Control of Swelling in Patients Attending Specialist Lymphedema Services. Lymphatic Research and Biology, 2019, 17, 211-220.	1.1	8
44	The Concept of Chronic Edemaâ€"A Neglected Public Health Issue and an International Response: The LIMPRINT Study. Lymphatic Research and Biology, 2019, 17, 121-126.	1.1	42
45	Prevalence and Risk Factors for Chronic Edema in U.K. Community Nursing Services. Lymphatic Research and Biology, 2019, 17, 147-154.	1.1	29
46	LIMPRINT: Estimation of the Prevalence of Lymphoedema/Chronic Oedema in Acute Hospital in In-Patients. Lymphatic Research and Biology, 2019, 17, 135-140.	1.1	16
47	Communication with patients using negative wound pressure therapy and their adherence to treatment. Journal of Wound Care, 2019, 28, 738-756.	1.2	2
48	Topical sirolimus 0.1% for treating cutaneous microcystic lymphatic malformations in children and adults (TOPICAL): protocol for a multicenter phase 2, within-person, randomized, double-blind, vehicle-controlled clinical trial. Trials, 2019, 20, 739.	1.6	17
49	Rate and duration of hospitalisation for acute pulmonary embolism in the real-world clinical practice of different countries: analysis from the RIETE registry. European Respiratory Journal, 2019, 53, 1801677.	6.7	13
50	Urgent need to clarify the definition of chronic critical limb ischemia – a position paper from the European Society for Vascular Medicine. Vasa - European Journal of Vascular Medicine, 2019, 48, 223-227.	1.4	22
51	ESVM Guideline on peripheral arterial disease. Vasa - European Journal of Vascular Medicine, 2019, 48, 1-79.	1.4	110
52	Pulmonary Embolism Home Treatment: What GP Want?. Blood, 2019, 134, 4699-4699.	1.4	0
53	Correlation between capillaroscopic classifications and severity in systemic sclerosis: results from SCLEROCAP study at inclusion. Clinical and Experimental Rheumatology, 2019, 37 Suppl 119, 63-68.	0.8	4
54	Long-term outcomes of isolated superficial vein thrombosis in patients with active cancer. Thrombosis Research, 2018, 171, 179-186.	1.7	13

#	Article	IF	CITATIONS
55	Predictors of Post-Thrombotic Ulcer after Acute DVT: The RIETE Registry. Thrombosis and Haemostasis, 2018, 118, 320-328.	3.4	21
56	PMD140 - OUT-OF-POCKET PAYMENTS FOR MEDICAL DEVICES AND EQUITY IN HEALTHCARE FOR PATIENTS WITH PRIMARY LYMPHEDEMA IN FRANCE. Value in Health, 2018, 21, S267.	0.3	0
57	Venous Thromboembolism in Women Undergoing Assisted Reproductive Technologies: Data from the RIETE Registry. Thrombosis and Haemostasis, 2018, 118, 1962-1968.	3.4	48
58	Incidence of Cellulitis among Children with Primary Lymphedema. New England Journal of Medicine, 2018, 378, 2047-2048.	27.0	13
59	Epidemiology, patterns of care and mortality for patients with hemodynamically unstable acute symptomatic pulmonary embolism. International Journal of Cardiology, 2018, 269, 327-333.	1.7	41
60	Obstetric antiphospholipid syndrome: early variations of angiogenic factors are associated with adverse outcomes. Haematologica, 2017, 102, 835-842.	3.5	11
61	Longâ€ŧerm outcomes of cancerâ€related isolated distal deep vein thrombosis: the OPTIMEV study. Journal of Thrombosis and Haemostasis, 2017, 15, 907-916.	3.8	53
62	Interest of an auto-adjustable nighttime compression sleeve (MOBIDERM® Autofit) in maintenance phase of upper limb lymphedema: the MARILYN pilot RCT. Supportive Care in Cancer, 2017, 25, 2455-2462.	2.2	23
63	Longâ€ŧerm risk of venous thromboembolism recurrence after isolated superficial vein thrombosis. Journal of Thrombosis and Haemostasis, 2017, 15, 1123-1131.	3.8	33
64	The safety and efficacy of full-versus reduced-dose betrixaban in the Acute Medically III VTE (Venous) Tj ETQq0 C Journal, 2017, 185, 93-100.	0 0 rgBT /C 2.7	Overlock 10 Tf 48
65	Psychological Factors in Chronic Edema: A Case–Control Study. Lymphatic Research and Biology, 2017, 15, 252-261.	1.1	11
66	Comparison of Fatal or Irreversible Events With Extendedâ€Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. Journal of the American Heart Association, 2017, 6, .	3.7	40
67	Reproducibility of capillaroscopic classifications of systemic sclerosis: results from the SCLEROCAP study. Rheumatology, 2017, 56, 1713-1720.	1.9	27
68	Germline Loss-of-Function Mutations in EPHB4 Cause a Second Form of Capillary Malformation-Arteriovenous Malformation (CM-AVM2) Deregulating RAS-MAPK Signaling. Circulation, 2017, 136, 1037-1048.	1.6	204
69	Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically III Patients. Circulation, 2017, 135, 648-655.	1.6	61
70	An Auto-Adjustable Night Garment to Control Early Rebound Effect of Edema Volume After Intensive Phase of Decongestive Lymphedema Therapy. Lymphatic Research and Biology, 2017, 15, 364-370.	1,1	3
71	A 2D Computational Model of Lymphedema and of its Management with Compression Device. Mathematical Modelling of Natural Phenomena, 2017, 12, 180-195.	2.4	5
72	HyperhomocystÃ@inÃ@mie etÂthromboses artÃ@rielles. , 2016, , 505-507.		0

#	Article	IF	CITATIONS
73	Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial. Lancet Haematology, the, 2016, 3, e556-e562.	4.6	135
74	Healthcare Expenditures and Equity in Healthcare Utilization for Lymphedema Patients in France. Value in Health, 2016, 19, A704.	0.3	0
75	Extended Thromboprophylaxis with Betrixaban in Acutely III Medical Patients. New England Journal of Medicine, 2016, 375, 534-544.	27.0	379
76	Life-Threatening Cutaneous Bleeding in Childhood Klippel-Trenaunay Syndrome Treated With Oral Sirolimus. JAMA Dermatology, 2016, 152, 1058.	4.1	14
77	Imbalance of the Vanin-1 Pathway in Systemic Sclerosis. Journal of Immunology, 2016, 197, 3326-3335.	0.8	28
78	Combining balneotherapy and health promotion to promote active and healthy ageing: the Balaruc-MACVIA-LR® approach. Aging Clinical and Experimental Research, 2016, 28, 1061-1065.	2.9	21
79	OUT-OF-POCKET PAYMENTS FOR PATIENTS WITH LYMPHEDEMA IN FRANCE: A DISTRIBUTIONAL ANALYSIS. Value in Health, 2016, 19, A309-A310.	0.3	1
80	Prevalence, Clinical Characteristics, and Risk Factors for Non-recording of Alcohol Use in Hospitals across Europe: The ALCHIMIE Study. Alcohol and Alcoholism, 2016, 51, 457-464.	1.6	10
81	Artériopathie oblitérante desÂmembres inférieurs : éducation thérapeutique duÂpatient. , 2016, , 283	-285.	0
82	MACVIA-LR (FIGHTING CHRONIC DISEASES FOR ACTIVE AND HEALTHY AGEING IN LANGUEDOC-ROUSSILLON): A SUCCESS STORY OF THE EUROPEAN INNOVATION PARTNERSHIP ON ACTIVE AND HEALTHY AGEING. Journal of Frailty & Damp; Aging, the, 2016, 5, 1-9.	1.3	8
83	Is it useful to also image the asymptomatic leg in patients with suspected deep vein thrombosis?: comment. Journal of Thrombosis and Haemostasis, 2015, 13, 2127-2130.	3.8	1
84	Practice variation in the management of distal deep vein thrombosis in primary vs. secondary cares: A clinical practice survey. Thrombosis Research, 2015, 136, 526-530.	1.7	19
85	Effect of a Retrievable Inferior Vena Cava Filter Plus Anticoagulation vs Anticoagulation Alone on Risk of Recurrent Pulmonary Embolism. JAMA - Journal of the American Medical Association, 2015, 313, 1627.	7.4	404
86	Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Annals of the Rheumatic Diseases, 2015, 74, 1011-1018.	0.9	610
87	Anatomical Predictors of Venous Thromboembolism Recurrence after Isolated Superficial Vein Thrombosis. Blood, 2015, 126, 651-651.	1.4	2
88	Impact of anatomical location of lower limb venous thrombus on the risk of subsequent cancer. Thrombosis and Haemostasis, 2014, 112, 1129-1136.	3.4	20
89	Incidence and predictors of venous thromboembolism recurrence after a first isolated distal deep vein thrombosis. Journal of Thrombosis and Haemostasis, 2014, 12, 436-443.	3.8	106
90	Use of bosentan for digital ulcers related to systemic sclerosis: a real-life retrospective French study of 89 patients treated since specific approval. Scandinavian Journal of Rheumatology, 2014, 43, 398-402.	1.1	12

#	Article	IF	CITATIONS
91	Perioperative and peripartum prevention of venous thromboembolism in patients with hereditary antithrombin deficiency using recombinant antithrombin therapy. Blood Coagulation and Fibrinolysis, 2014, 25, 444-450.	1.0	18
92	Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis. JAMA - Journal of the American Medical Association, 2014, 311, 2490.	7.4	566
93	Validation of lower limb segmental volumetry with hand-held, self-positioning three-dimensional laser scanner against water displacement. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2014, 2, 39-45.	1.6	17
94	Compression stockings to prevent post-thrombotic syndrome. Lancet, The, 2014, 384, 129.	13.7	37
95	Characteristics, prognosis, and outcomes of cutaneous ischemia and gangrene in systemic necrotizing vasculitides: A retrospective multicenter study. Seminars in Arthritis and Rheumatism, 2014, 43, 681-688.	3.4	15
96	Genotypes and Phenotypes of 162 Families with aGlomulinMutation. Molecular Syndromology, 2013, 4, 157-64.	0.8	55
97	Mutations in the VEGFR3 Signaling Pathway Explain 36% of Familial Lymphedema. Molecular Syndromology, 2013, 4, 257-266.	0.8	92
98	Clinical relevance of symptomatic superficial-vein thrombosis extension: lessons from the CALISTO study. Blood, 2013, 122, 1724-1729.	1.4	35
99	FRIO253â€Use of bosentan for the prevention of digital ulcers related to systemic sclerosis. Retrospective french study of 89 patients treated since 2007. Annals of the Rheumatic Diseases, 2013, 71, 399.4-400.	0.9	0
100	Comparative incidence of a first thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational study. Blood, 2012, 119, 2624-2632.	1.4	101
101	Mondor's disease: What's new since 1939?. Thrombosis Research, 2012, 130, S56-S58.	1.7	39
102	Epidemiology, diagnosis, treatment and management of superficial-vein thrombosis of the legs. Best Practice and Research in Clinical Haematology, 2012, 25, 275-284.	1.7	48
103	Superficial venous thrombosis and compression ultrasound imaging. Journal of Vascular Surgery, 2012, 56, 1032-1038.e1.	1.1	34
104	A randomized double-blind trial of upward progressive versus degressive compressive stockings in patients with moderate to severe chronic venous insufficiency. Journal of Vascular Surgery, 2012, 56, 1344-1350.e1.	1.1	49
105	Autosomal dominant polycystic kidney disease: Comprehensive mutation analysis of PKD1 and PKD2 in 700 unrelated patients. Human Mutation, 2012, 33, 1239-1250.	2.5	144
106	Value of a Planned Compression Ultrasonography after an Isolated Superficial Vein Thrombosis: Results from a Prospective Multicentre Study. European Journal of Vascular and Endovascular Surgery, 2012, 43, 233-237.	1.5	14
107	Superficial vein thrombosis and recurrent venous thromboembolism: a pooled analysis of two observational studies. Journal of Thrombosis and Haemostasis, 2012, 10, 1004-1011.	3.8	39
108	Autologous Hematopoietic Stem Cell Transplantation Versus Intravenous Pulse Therapy Cyclophosphamide for Severe or Rapidly Progressive Systemic Sclerosis, the Astis Trial. Blood, 2012, 120, 964-964.	1.4	5

#	Article	IF	Citations
109	Recent findings in the epidemiology, diagnosis and treatment of superficial-vein thrombosis. Thrombosis Research, 2011, 127, S81-S85.	1.7	32
110	0.07a Enoxaparin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia: the pilot randomised controlled NOH-PE study. Thrombosis Research, 2011, 127, S126.	1.7	0
111	Predictive factors for concurrent deep-vein thrombosis and symptomatic venous thromboembolic recurrence in case of superficial venous thrombosis. Thrombosis and Haemostasis, 2011, 105, 31-39.	3.4	79
112	Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia. Thrombosis and Haemostasis, 2011, 106, 1053-1061.	3.4	88
113	Risk factors and early outcomes of patients with symptomatic distal vs. proximal deep-vein thrombosis. Current Opinion in Pulmonary Medicine, 2011, 17, 387-391.	2.6	26
114	Venous Thromboembolism Risk and Prophylaxis in the Acute Care Hospital Setting (ENDORSE Survey). Annals of Surgery, 2010, 251, 330-338.	4.2	93
115	2008 french national guidelines for the treatment of venous thromboembolism in patients with cancer: Report from the working group. Critical Reviews in Oncology/Hematology, 2010, 73, 31-46.	4.4	78
116	Validation of a Fully Automatic Photoplethysmographic Device for Toe Blood Pressure Measurement. European Journal of Vascular and Endovascular Surgery, 2010, 40, 515-520.	1.5	38
117	Paternal endothelial protein C receptor 219Gly variant as a mild and limited risk factor for deep vein thrombosis during pregnancy. Journal of Thrombosis and Haemostasis, 2010, 8, 707-713.	3.8	11
118	Enoxaparin for the secondary prevention of placental vascular complications in women with abruptio placentae. Thrombosis and Haemostasis, 2010, 104, 771-779.	3.4	79
119	Superficial Venous Thrombosis and Venous Thromboembolism. Annals of Internal Medicine, 2010, 152, 218.	3.9	287
120	Clinical presentation and mortality in pulmonary embolism: The Optimev study. Journal Des Maladies Vasculaires, 2010, 35, 242-249.	0.6	17
121	Venous thromboembolism risk and prophylaxis in hospitalised medically ill patients. Thrombosis and Haemostasis, 2010, 103, 736-748.	3.4	86
122	Comparison of the clinical history of symptomatic isolated muscular calf vein thrombosis versus deep calf vein thrombosis. Journal of Vascular Surgery, 2010, 52, 932-938.e2.	1.1	43
123	Outcomes for Inpatients with Normal Findings on Whole-leg Ultrasonography: A Prospective Study. American Journal of Medicine, 2010, 123, 158-165.	1.5	24
124	Risk for Venous Thromboembolism in Patients With Superficial Venous Thrombosis. Annals of Internal Medicine, 2010, 153, 63.	3.9	0
125	Exploration desÂmalformations vasculaires. Sang Thrombose Vaisseaux, 2009, 21, 023-029.	0.1	2
126	Accuracy of complete compression ultrasound in ruling out suspected deep venous thrombosis in the ambulatory setting. Thrombosis and Haemostasis, 2009, 102, 166-172.	3.4	37

#	Article	IF	CITATIONS
127	Ultrasound-Based Diagnostic Strategies for Deep Vein Thrombosis. JAMA - Journal of the American Medical Association, 2009, 301, 933.	7.4	10
128	Comparison of the clinical history of symptomatic isolated distal deepâ€vein thrombosis vs. proximal deep vein thrombosis in 11â€f086 patients. Journal of Thrombosis and Haemostasis, 2009, 7, 2028-2034.	3.8	102
129	Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Annals of the Rheumatic Diseases, 2009, 68, 1428-1432.	0.9	262
130	Comparative study on risk factors and early outcome of symptomatic distal versus proximal deep vein thrombosis: Results from the OPTIMEV study. Thrombosis and Haemostasis, 2009, 102, 493-500.	3.4	131
131	Thromboses veineuses distales: encore uneÂsource deÂdiscorde LesÂraisons deÂl'étude CACTUS. Sang Thrombose Vaisseaux, 2009, 21, 315-321.	0.1	1
132	Parkes Weber syndrome, vein of Galen aneurysmal malformation, and other fast-flow vascular anomalies are caused by RASA1 mutations. Human Mutation, 2008, 29, 959-965.	2.5	382
133	Standards, optionsÂ: recommandations 2008. Traitement curatif de la maladie thromboembolique veineuse chez les patients atteints de cancer. Revue De Medecine Interne, 2008, 29, 1068-1079.	1.0	1
134	Standards, optionsÂ: recommandations 2008. Prévention et traitement des thromboses veineuses sur cathéter chez les patients atteints de cancer. Revue De Medecine Interne, 2008, 29, 1058-1067.	1.0	0
135	Aspirin response variability assessed with the PFA-100 device. Thrombosis and Haemostasis, 2008, 99, 968-969.	3.4	5
136	A clinical prediction score for upper extremity deep venous thrombosis. Thrombosis and Haemostasis, 2008, 99, 202-207.	3.4	107
137	48 The EPCR Ser219Gly polymorphism is associated with the risk of unexplained foetal death in couples in the NOHA First matched case-control study. Thrombosis Research, 2007, 119, S110.	1.7	0
138	Homozygosity for the C46T polymorphism of the F12 gene is a risk factor for venous thrombosis during the first pregnancy. Journal of Thrombosis and Haemostasis, 2007, 5, 700-707.	3.8	28
139	Outcome of the subsequent pregnancy after a first loss in women with factor V Leiden or prothrombin 20210A mutation: a rebuttal. Journal of Thrombosis and Haemostasis, 2007, 5, 1990-1992.	3.8	2
140	About the significance or the insignificance of the factor XII C46T polymorphism: reply to a rebuttal. Journal of Thrombosis and Haemostasis, 2007, 5, 2163-2165.	3.8	2
141	Risk Factors for Isolated Pulmonary Embolism Are Opposite to Those for DVT-Associated PE: Results of the 7532-Patients Prospective OPTIMEV Cohort Study Blood, 2007, 110, 3977-3977.	1.4	1
142	Recurrence and Mortality of DVT-Associated PE Is Greater Than Isolated PE Alone: Results of the 7532-Patients Prospective OPTIMEV Cohort Study Blood, 2007, 110, 700-700.	1.4	5
143	Monitoring the Effects and Managing the Side Effects of Anticoagulation during Pregnancy. Obstetrics and Gynecology Clinics of North America, 2006, 33, 397-411.	1.9	10
144	Prophylaxis and treatment of thrombophilia in pregnancy. Current Opinion in Hematology, 2006, 13, 376-381.	2.5	19

#	Article	IF	CITATIONS
145	Postpartum residual venous obstruction of the lower limbs in the matched case-control â€NOHA first' study on miscarriage. Journal of Thrombosis and Haemostasis, 2006, 4, 2493-2495.	3.8	1
146	International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients With Atherothrombosis. JAMA - Journal of the American Medical Association, 2006, 295, 180.	7.4	1,353
147	Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events. New England Journal of Medicine, 2006, 354, 1706-1717.	27.0	2,582
148	Diffuse skin necrosis in a patient with an anti-endothelial cell protein C receptor autoantibody which blocks protein C activation. Journal of Thrombosis and Haemostasis, 2005, 3, 413-415.	3.8	5
149	Factor V Leiden and prothrombin G20210A polymorphisms as risk factors for miscarriage during a first intended pregnancy: the matched case-control â€`NOHA first' study. Journal of Thrombosis and Haemostasis, 2005, 3, 2178-2184.	3.8	98
150	Homocysteine and Venous Thrombosis. Seminars in Vascular Medicine, 2005, 5, 183-189.	2.1	22
151	VEGF and KDR Gene Expression during Human Embryonic and Fetal Eye Development. , 2004, 45, 7.		75
152	Genomic rearrangements in the CFTR gene: Extensive allelic heterogeneity and diverse mutational mechanisms. Human Mutation, 2004, 23, 343-357.	2.5	115
153	Past, Present and Future of Arterial Endofibrosis in Athletes. Sports Medicine, 2004, 34, 419-425.	6.5	26
154	HAMP as a modifier gene that increases the phenotypic expression of the HFE pC282Y homozygous genotype. Blood, 2004, 103, 2835-2840.	1.4	152
155	Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood, 2004, 103, 3695-3699.	1.4	389
156	Thrombophilic families with inheritably associated high levels of coagulation factors VIII, IX and XI. Journal of Thrombosis and Haemostasis, 2003, 1, 2134-2139.	3.8	23
157	Essoufflée? En effet Quel effet ?. Revue De Medecine Interne, 2003, 24, 203s-204s.	1.0	0
158	Influence of Centrifugation Temperature on the Plasma Total Homocysteine Concentration. Clinical Chemistry, 2003, 49, 1026-1027.	3.2	1
159	Wall Mechanics of the Stented Extracranial Carotid Artery. Stroke, 2003, 34, e222-4.	2.0	34
160	Anti–protein Z antibodies in women with pathologic pregnancies. Blood, 2003, 101, 4850-4852.	1.4	51
161	Antiphospholipid/antiprotein antibodies, hemostasis-related autoantibodies, and plasma homocysteine as risk factors for a first early pregnancy loss: a matched case-control study. Blood, 2003, 102, 3504-3513.	1.4	90
162	Prenatal detection of cystic fibrosis by ultrasonography: a retrospective study of more than 346 000 pregnancies. Journal of Medical Genetics, 2002, 39, 443-448.	3.2	36

#	Article	IF	CITATIONS
163	Determination of the relative contribution of three genesâ€"the cystic fibrosis transmembrane conductance regulator gene, the cationic trypsinogen gene, and the pancreatic secretory trypsin inhibitor geneâ€"to the etiology of idiopathic chronic pancreatitis. European Journal of Human Genetics, 2002, 10, 100-106.	2.8	131
164	High frequency of protein Z deficiency in patients with unexplained early fetal loss. Blood, 2002, 99, 2606-2608.	1.4	103
165	Association between the methylenetetrahydrofolate reductase 677C>T polymorphism and the risk of secondary lymphoproliferative disease in patients with a first idiopathic thrombosis. Blood, 2002, 100, 735-736.	1.4	0
166	Red blood cell methylfolate and plasma homocysteine as risk factors for venous thromboembolism: a matched case-control study. Lancet, The, 2002, 359, 747-752.	13.7	87
167	Measurement of red blood cell methylfolate. Lancet, The, 2002, 360, 1022.	13.7	0
168	L'hyperhomocystéinémie estelle réellement un facteur de risque vasculaire?. Revue De Medecine Interne, 2002, 23, 6s.	1.0	0
169	Enoxaparin Sodium Improves Pregnancy Outcome in Aspirin-resistant Antiphospholipid/Antiprotein Antibody Syndromes. Thrombosis and Haemostasis, 2002, 87, 536-537.	3.4	12
170	Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis and Rheumatism, 2002, 46, 1019-1027.	6.7	1,736
171	Validation of a newly developed B-mode image-processing technique versus wall-tracking ultrasound for the study of wall mechanics in small-calibre arteries. Clinical Physiology and Functional Imaging, 2002, 22, 180-186.	1.2	7
172	Mutations of the pancreatic secretory trypsin inhibitor (PSTI) gene in idiopathic chronic pancreatitis. Gastroenterology, 2001, 120, 1061-1063.	1.3	100
173	Vitamin supplementation and pregnancy outcome in women with recurrent early pregnancy loss and hyperhomocysteinemia. Fertility and Sterility, 2001, 75, 823-825.	1.0	67
174	Identification of a Novel Pancreatitis-Associated Missense Mutation, R116C, in the Human Cationic Trypsinogen Gene (PRSS1). Molecular Genetics and Metabolism, 2001, 74, 342-344.	1.1	35
175	APC resistance and third-generation oral contraceptives. Human Reproduction, 2001, 16, 3-8.	0.9	18
176	Discrimination of three mutational events that result in a disruption of the R122 primary autolysis site of the human cationic trypsinogen (PRSS1) by denaturing high performance liquid chromatography. BMC Genetics, 2001, 2, 19.	2.7	42
177	Modulation of COX-2 Expression by Statins in Human Aortic Smooth Muscle Cells. Journal of Biological Chemistry, 2001, 276, 46849-46855.	3.4	89
178	Cutaneous thrombotic and necrotizing microangiopathy revealing a large granular lymphocytic leukaemia. British Journal of Dermatology, 2000, 143, 445-446.	1.5	6
179	Antiphospholipid and Antiprotein Syndromes in Non-thrombotic, Non-autoimmune Women with Unexplained Recurrent Primary Early Foetal Loss. Thrombosis and Haemostasis, 2000, 84, 228-236.	3.4	126
180	Neonatal screening for cystic fibrosis in Brittany, France: assessment of 10 years' experience and impact on prenatal diagnosis. Lancet, The, 2000, 356, 789-794.	13.7	97

#	Article	lF	CITATIONS
181	Case-control Study of the Frequency of Thrombophilic Disorders in Couples with Late Foetal Loss and no Thrombotic Antecedent. Thrombosis and Haemostasis, 1999, 81, 891-899.	3.4	205
182	The 20210A Allele of the Prothrombin Gene Is an Independent Risk Factor for Perception Deafness in Patients With Venous Thromboembolic Antecedents. Blood, 1999, 93, 3150-3152.	1.4	25
183	Spatial and Temporal Expression of the Cystathionine \hat{l}^2 -Synthase Gene During Early Human Development. Biochemical and Biophysical Research Communications, 1999, 254, 127-137.	2.1	57
184	A woman with five consecutive fetal deaths: Case report and retrospective analysis of hyperhomocysteinemia prevalence in 100 consecutive women with recurrent miscarriages. Fertility and Sterility, 1998, 69, 152-154.	1.0	91
185	Induction of Endothelial Cell Adhesion Molecules by Serum and Immunoglobulins G from a Patient with Vasculitis and Monoclonal Gammapathy: Potential Relevance to Vasculitis. Thrombosis and Haemostasis, 1998, 80, 477-480.	3.4	49
186	The 20210A Allele of the Prothrombin Gene Is Frequent in Young Women With Unexplained Spinal Cord Infarction. Blood, 1998, 92, 1840-1841.	1.4	14
187	Primary Recurrent Miscarriages: Anti–β2-Glycoprotein I IgG Antibodies Induce an Acquired Activated Protein C Resistance That Can Be Detected by the Modified Activated Protein C Resistance Test. Blood, 1998, 92, 2993-2994.	1.4	13
188	Effects of homocysteine on acetylcholine- and adenosine-induced vasodilatation of pancreatic vascular bed in rats. British Journal of Pharmacology, 1997, 122, 351-357.	5 . 4	33
189	Diagnosis of acute lower limb deep venous thrombosis with ultrasound: Trends and controversies. , 1997, 25, 343-358.		58
190	Human Longevity and R506Q Factor V Gene Mutation. Thrombosis and Haemostasis, 1997, 78, 1160-1160.	3.4	7
191	Thrombophilia, Homocystinuria, and Mutation of the Factor V Gene. New England Journal of Medicine, 1996, 335, 289-290.	27.0	32
192	Determination of the relative contribution of three genes–the cystic fibrosis transmembrane conductance regulator gene, the cationic trypsinogen gene, and the pancreatic secretory trypsin inhibitor gene–to the etiology of idiopathic chronic pancreatitis. , 0, .		1